Investors buy marijuana stocks for the potential high they can provide, but on Hump Day, Curaleaf (OTC: CURLF) produced the wrong kind of buzz. The veteran pot company saw its share price sag by almost 5% on the day, on the back of a discouraging media report about weed legalization. That was a far more pronounced slide than the S&P 500‘s (SNPINDEX: ^GSPC) decrease of 1.6%.
Pot reform resistance?
An article published well before market open in The New York Times that day detailed the stalling effort to effectively decriminalize marijuana sale and consumption.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Image source: Getty Images.
Although both have been legalized at the state level in many instances, technically the drug remains illegal per federal law. In the Drug Enforcement Agency’s (DEA) schedule of drugs, marijuana is categorized as Schedule I. In the agency’s language, this means it is a substance “with no currently accepted medical use and a high potential for abuse.”
Citing unnamed “leading supporters and critics” of marijuana law reform efforts, the article stated that continued resistance from DEA officials has slowed the process of reform. It also pointed out that, despite implying on the campaign trail that reform would occur if he were to be elected, President Donald Trump’s administration released a drug policy blueprint that didn’t include it.
Ignoring the wishes of the public
Neither the White House nor the DEA has yet commented on the Times article, and isn’t likely to. There is an odd dichotomy in this country about marijuana reform: It is broadly supported by the public; however, the few moves made by politicians and law enforcement figures aren’t producing results. Hopefully that will change in the very near future, or Curaleaf and its marijuana industry peers will struggle even more.
Should you invest $1,000 in Curaleaf right now?
Before you buy stock in Curaleaf, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Curaleaf wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $642,582!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $829,879!*
Now, it’s worth noting Stock Advisor’s total average return is 975% — a market-crushing outperformance compared to 172% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
